Screener
Cytek Biosciences, Inc. CTKB Deferred Revenue
Deferred Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, current | 29,206 | 28,504 |
| Total current liabilities | 84,335 | 77,804 |
| Legal settlement liability, noncurrent | 6,368 | 6,786 |
| Deferred revenue, noncurrent | 18,058 | 18,339 |
| Operating lease liability, noncurrent | 13,517 | 14,042 |
| Long-term debt | 246 | 525 |
| Other noncurrent liabilities | 2,456 | 2,307 |
| Total liabilities | 124,980 | 119,803 |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s deferred revenue?
- Cytek Biosciences, Inc. (CTKB) reported deferred revenue of $18.06M in Q2 2026.
- How has Cytek Biosciences, Inc.'s deferred revenue changed year-over-year?
- Cytek Biosciences, Inc.'s deferred revenue increased by 8.6% year-over-year, from $16.63M to $18.06M.
- What is the long-term trend for Cytek Biosciences, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s deferred revenue has grown at a 52.5% compound annual growth rate (CAGR), from $3.46M to $28.5M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Cytek Biosciences, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude